This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG – Research Report), ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Intuitive ...

Regeneron Pharmaceuticals (REGN) has inked a $3B deal with contract drug developer FUJIFILM Diosynth Biotechnologies (FUJIY) ...

The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for the indication. The approval makes ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...